On 26 November 2025, Swissmedic issued an official notice regarding the immediate recall of batch 1653102 of Lexotanil 3mg Tablets. This action targets distribution at the retail level and aims to prevent further circulation of affected units. Clinical, quality, and regulatory stakeholders are advised to review the announcement carefully and implement appropriate measures.
Jump to:
What changed?
The batch recall pertains specifically to Lexotanil 3mg Tablets, identified by batch number 1653102. Swissmedic’s directive requires that all distribution be halted at the retail level to mitigate risks associated with quality concerns. Details of the precise issue have not been disclosed, but stakeholders must act swiftly to comply.
Details of the recall
The decision to recall this batch underscores Swissmedic’s commitment to upholding pharmaceutical quality and patient safety. The agency’s notice indicates that the action only affects the specified batch, and other batches remain unaffected. Affected units should be withdrawn from shelves immediately pending further investigation or instructions from regulatory authorities.
Healthcare providers and retailers are encouraged to collaborate in identifying impacted units and ensuring they are safely removed from circulation. Documentation should also reflect these activities as part of compliance protocols.
Who is affected?
This recall directly impacts retail outlets distributing Lexotanil 3mg Tablets from batch 1653102. Clinical practitioners and pharmacies may encounter interrupted supplies, potentially affecting patients relying on this medication. Regulatory and quality assurance teams must coordinate efforts to assess inventory, inform stakeholders, and verify adherence.
Patients are advised to consult healthcare providers for guidance if concerns arise regarding their medication. Any inquiries about alternatives or adjustments should be directed to a certified medical professional.
FAQ
Q1: Why is this batch being recalled?
Affected units pose potential quality risks. While Swissmedic’s notice did not provide exact reasons, compliance is required.
Q2: Are all Lexotanil tablets impacted?
No. The recall applies to batch 1653102 only; other batches remain unaffected.
Q3: What should retailers do?
Retailers must remove impacted products from shelves immediately and ensure proper documentation for compliance purposes.
Conclusion
Swissmedic’s batch recall highlights the importance of quality assurance in pharmaceuticals. Retailers, healthcare practitioners, and regulatory teams must prioritize compliance and patient safety in managing this recall.
Disclaimer
This article is intended for informational purposes only and should not be construed as legal or clinical advice. Consult Swissmedic or appropriate regulatory entities for official guidance.
Swissmedic notice
For full information about the Swissmedic announcement, see the link below.